Efficient inhibition of emerging SARS-CoV-2 variants including NB.1.8.1, XFG and BA.3.2 by a fusion inhibitor HY3000 peptide
-
-
REFERENCES
[1] Du P., Li J., Kong T., et al. (2025). Defining the serotypes of SARS-CoV-2 subvariants up to December, 2024. Lancet. Microbe. 6:e101124. DOI:10.1016/j.lanmic.2025.101124 [2] Su H., Zhang J., Yi Z., et al. (2024). A human monoclonal antibody neutralizes SARS-CoV-2 Omicron variants by targeting the upstream region of spike protein HR2 motif. hLife. 2:126−140. DOI:10.1016/j.hlife.2024.02.001 [3] Tong Z., Tong J., Lei W., et al. (2024). Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1. Cell. Rep. 43:114338. DOI: 10.1016/j.celrep.2024.114338 [4] Li C., Zhan W., Yang Z., et al. (2022). Broad neutralization of SARS-CoV-2 variants by an inhalable bispecific single-domain antibody. Cell. 185:1389−1401.e18. DOI:10.1016/j.cell.2022.03.009 [5] Liu H., Wu L., Liu B., et al. (2023). Two pan-SARS-CoV-2 nanobodies and their multivalent derivatives effectively prevent Omicron infections in mice. Cell. Rep. Med. 4:100918. DOI:10.1016/j.xcrm.2023.100918 [6] Liu B., Liu H., Han P., et al. (2024). Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain. Sig. Transduct. Target. Ther. 9:2726−2737. DOI:10.1038/s41392-024-01847-8 [7] Wang X., Xie Y., Liu H., et al. (2024). A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses. Sci. Bull. 68:684−687. DOI:10.1016/j.scib.2023.03.027 [8] Wu L., Zheng A., Tang Y., et al. (2023). A pan-coronavirus peptide inhibitor prevents SARS-CoV-2 infection in mice by intranasal delivery. Sci. China. Life. Sci. 66:2201−2213. DOI:10.1007/s11427-023-2410-5 [9] Wu L., Zheng A., Tang Y., et al. (2024). Efficient inhibition of SARS-CoV-2 emerging EG.5, EG.5.1 and BA.2.86 variants by fusion inhibitor HY3000 peptide. hLife. 2:43-46. DOI:10.1016/j.hlife.2023.10.002 [10] Guo C., Yu Y., Liu J., et al. (2025). Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1. Lancet. Infect. Dis. 25:e374-e377. DOI: 10.1016/S1473-3099(25)00308-1 -
ABOUT THIS ARTICLE
Cite this article:
Liu W., Wu L., Li J., et al. (2026). Efficient inhibition of emerging SARS-CoV-2 variants including NB.1.8.1, XFG and BA.3.2 by a fusion inhibitor HY3000 peptide. The Innovation Life 4:100184. https://doi.org/10.59717/j.xinn-life.2026.100184
Welcome!
To request copyright permission to republish or share portions of our works, please visit Copyright Clearance Center's (CCC) Marketplace website at marketplace.copyright.com.
Export File
Citation
Liu W., Wu L., Li J., et al. (2026). Efficient inhibition of emerging SARS-CoV-2 variants including NB.1.8.1, XFG and BA.3.2 by a fusion inhibitor HY3000 peptide. The Innovation Life 4:100184. https://doi.org/10.59717/j.xinn-life.2026.100184
Format
Content
DownLoad:
-
Figure 1.
Amino acid mutation profiling of the S2 subunit of SARS-CoV-2 spike (S) proteins from emerging variants, and inhibitory activities of the HY3000 peptide against corresponding pseudoviruses
